SS
MLTX icon

SBI Securities’s MoonLake Immunotherapeutics MLTX Stock Holding History

SBI Securities’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.17K Buy
368
+155
+73% +$2.81K ﹤0.01% 2009
2026
Q1 		$3.97K Hold
213
– – ﹤0.01% 2129
2025
Q4 		$2.81K Sell
213
-739
-78% -$8.72K ﹤0.01% 2264
2025
Q3 		$6.83K Buy
+952
New +$49.6K ﹤0.01% 1925

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SBI Securities's MLTX Position: Q2 2026 in Review

SBI Securities increased its MoonLake Immunotherapeutics (MLTX) stake by 73% in Q2 2026, buying an estimated $2.81K and bringing the position to 368 shares worth $7.17K. The position accounts for ﹤0.01% of the portfolio, ranked #2009.

SBI Securities first reported a position in MLTX in Q3 2025 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • SBI Securities held 368 shares of MoonLake Immunotherapeutics worth $7.17K as of Q2 2026.
  • SBI Securities bought 155 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $2.81K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2009 holding.
  • SBI Securities first reported a position in MoonLake Immunotherapeutics in Q3 2025 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.